Inmune Bio, Inc. (INMB): Cash & Equivalents
$24.75M
As of 2025-12-31
-22.0%
3-year compound annual growth
+2.4%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.75M | +18.3% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $20.92M | -41.6% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $35.85M | -31.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $52.15M | -30.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $74.81M | +240.6% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $21.97M | +214.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $7.00M | n/m | 2021-03-04, Balance as of period end |
| 2018-12-31 | $186.2K | -86.4% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $1.37M | n/a | 2019-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $2.98M | +75.5% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $5.02M | -55.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗